Editorial
- Page Path
-
- HOME
- ARTICLE CATEGORY
- Editorial
- Editorial
- The latest evidence on the impact of fatty liver on liver-related outcomes and mortality in chronic hepatitis B
- Xianhua Mao, Lung Yi Mak, Wai-Kay Seto
- Clin Mol Hepatol. 2023;29(3):690-692. Published online May 30, 2023
-
View: 845 Download: 61
- The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review
- Young-Joo Jin
- Clin Mol Hepatol. 2023;29(2):414-416. Published online February 28, 2023
-
View: 3109 Download: 54
- How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
- Byeong Geun Song, Dong Hyun Sinn
- Clin Mol Hepatol. 2023;29(2):411-413. Published online March 6, 2023
-
View: 1198 Download: 36
- The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
- Ji-Won Park, Ki Tae Suk
- Clin Mol Hepatol. 2023;29(2):408-410. Published online March 16, 2023
-
View: 1268 Download: 47
- Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
- Margaret LP Teng, Darren Jun Hao Tan, Cheng Han Ng, Daniel Q. Huang
- Clin Mol Hepatol. 2023;29(2):404-407. Published online March 14, 2023
-
View: 1491 Download: 53 Citation: 1
- Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
- Kee-Huat Chuah, Wah-Kheong Chan
- Clin Mol Hepatol. 2023;29(2):401-403. Published online February 28, 2023
-
View: 1349 Download: 43
- Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
- Maamon Basheer, Mohamed Naffaa, Nimer Assy
- Clin Mol Hepatol. 2023;29(2):398-400. Published online February 13, 2023
-
View: 1531 Download: 91
- Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
- Lynna Alnimer, Mazen Noureddin
- Clin Mol Hepatol. 2023;29(2):394-397. Published online April 1, 2023
-
View: 1444 Download: 58
- Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
- Philipp Kasper, Münevver Demir, Hans-Michael Steffen
- Clin Mol Hepatol. 2023;29(2):390-393. Published online March 20, 2023
-
View: 1382 Download: 40 Citation: 1
- Implications of comorbidities in nonalcoholic fatty liver disease
- Sherlot Juan Song, Vincent Wai-Sun Wong
- Clin Mol Hepatol. 2023;29(2):384-389. Published online March 14, 2023
-
View: 1707 Download: 63
- Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
- Heejoon Jang, Won Kim
- Clin Mol Hepatol. 2023;29(2):381-383. Published online March 9, 2023
-
View: 1523 Download: 61 Citation: 1
- Lean vs. obese phenotypes of nonalcoholic fatty liver disease: similar or different?
- Ho Soo Chun, Minjong Lee
- Clin Mol Hepatol. 2023;29(2):377-380. Published online March 9, 2023
-
View: 1398 Download: 67
- The growing burden of non-alcoholic fatty liver disease on mortality
- Ju-Yeon Cho, Won Sohn
- Clin Mol Hepatol. 2023;29(2):374-376. Published online March 6, 2023
-
View: 1270 Download: 49
- Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
- Eileen Laurel Yoon, Dae Won Jun
- Clin Mol Hepatol. 2023;29(2):371-373. Published online March 14, 2023
-
View: 1536 Download: 80
- Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?
- Joo Hyun Oh, Dong Hyun Sinn
- Clin Mol Hepatol. 2023;29(2):367-370. Published online March 20, 2023
-
DOI: https://doi.org/10.3350/cmh.2023.0054 Correction in: Clin Mol Hepatol 2023;29(3):828
-
View: 1381 Download: 49 Citations: 2
- The imitator of immune-tolerant chronic hepatitis B: A killer in disguise
- Moon Haeng Hur, Jeong-Hoon Lee
- Clin Mol Hepatol. 2023;29(2):363-366. Published online March 9, 2023
-
View: 1412 Download: 62 Citation: 1
- The current trends in the health burden of primary liver cancer across the globe
- Peter Konyn, Aijaz Ahmed, Donghee Kim
- Clin Mol Hepatol. 2023;29(2):358-362. Published online March 14, 2023
-
View: 1579 Download: 44
- The latest global burden of liver cancer: A past and present threat
- Joo Hyun Oh, Dae Won Jun
- Clin Mol Hepatol. 2023;29(2):355-357. Published online March 9, 2023
-
View: 1505 Download: 61 Citations: 5
- Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan
- San-Chi Chen
- Clin Mol Hepatol. 2023;29(2):352-354. Published online March 20, 2023
-
View: 1393 Download: 48
- Clinical practice guidelines and real-world practice for hepatocellular carcinoma in Taiwan: Bridging the gap
- Shen-Yung Wang
- Clin Mol Hepatol. 2023;29(2):349-351. Published online March 20, 2023
-
View: 1378 Download: 40
- The prime time for management of hepatocellular carcinoma in Hong Kong
- Landon L. Chan, Stephen L. Chan
- Clin Mol Hepatol. 2023;29(2):345-348. Published online March 9, 2023
-
View: 1355 Download: 40
- Management of hepatocellular carcinoma in China: Seeking common grounds while reserving differences
- Tian Yang, Ming-Da Wang, Xin-Fei Xu, Chao Li, Han Wu, Feng Shen
- Clin Mol Hepatol. 2023;29(2):342-344. Published online March 16, 2023
-
View: 1546 Download: 39
- The clinical management of hepatocellular carcinoma in China: Progress and challenges
- Shan Shan, Jidong Jia
- Clin Mol Hepatol. 2023;29(2):339-341. Published online March 16, 2023
-
View: 1502 Download: 65
- Toward user-friendly and evidence-based practice guidelines for hepatocellular carcinoma
- Do Young Kim
- Clin Mol Hepatol. 2023;29(2):335-338. Published online March 20, 2023
-
View: 1441 Download: 39
- What should be done to reduce the discrepancy between guidelines and real-life practice for hepatocellular carcinoma in Korea?
- Min Kyung Park, Yoon Jun Kim
- Clin Mol Hepatol. 2023;29(2):332-334. Published online March 16, 2023
-
View: 1363 Download: 30
- New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
- Young-Suk Lim
- Clin Mol Hepatol. 2023;29(1):118-119. Published online November 29, 2022
-
View: 1994 Download: 130 Citations: 2
- Moving toward hepatitis B virus functional cure - the impact of on-treatment kinetics of serum viral markers
- Lilian Yan Liang, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Terry Cheuk-Fung Yip
- Clin Mol Hepatol. 2023;29(1):113-117. Published online October 31, 2022
-
View: 2060 Download: 81 Citations: 3
- Baveno VII criteria to predict decompensation in compensated advanced chronic liver disease: Still some shades of grey
- Susana G Rodrigues
- Clin Mol Hepatol. 2023;29(1):110-112. Published online December 12, 2022
-
View: 2227 Download: 71
- Non-invasive tests-based risk stratification: Baveno VII and beyond
- Georg Semmler, Mathias Jachs, Mattias Mandorfer
- Clin Mol Hepatol. 2023;29(1):105-109. Published online November 23, 2022
-
View: 2399 Download: 87 Citations: 3
- The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus
- Jeong-Ju Yoo, Sang Gyune Kim
- Clin Mol Hepatol. 2023;29(1):102-104. Published online November 10, 2022
-
View: 2054 Download: 111 Citation: 1
-
Clinical and
Molecular
HepatologyPrint ISSN: 2287-2728
Online ISSN: 2287-285X
-
-
- HBeAg-positive grey-zone patients: Treatment beyond guideline recommendations?
- Systemic therapy in advanced hepatocellular carcinoma
- Epidemiology and updated management for autoimmune liver disease
- Microbiome and metabolomics in alcoholic liver disease
- Personalized medicine in nonalcoholic fatty liver disease
- Acute on chronic liver failure in cirrhosis
- Current status and outcome of liver transplantation in South Korea
- History and future of hepatitis B virus control in South Korea
- Hepatocellular carcinoma statistics in South Korea
Impact Factor8.9First decision
09 Days
Publication after acceptance
06 Days
*Last 12 months
- MOST VIEWED (Last 6 months)
- MOST CITED (2021-2023)
|
|||||||
